Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Relief For Heron Therapeutics After The Court Win On Cinvanti
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but the company expects a recovery in Cinvanti sales in Q4 due to new account wins, and it shared encouraging trends of Zynrelef and Aponvie.
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William Forbes - Executive Vice President & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Serge Belanger - Needham Brandon Folkes - Rodman & Renshaw Operator Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post Q2 2024 Earnings of ($0.05) Per Share
Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Analysts at Capital One Financial increased their Q2 2024 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Wednesday, May 15th. Capital One Financial analyst T. Chiang now forecasts that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.07). Capital One Financial has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.10) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.03) EPS, FY2024 earnings at ($0.17) EPS and FY2025 earnings at $0.02 EPS. Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a report on Thursday. Read Our Latest Stock Analysis on HRTX Heron Therapeutics Price Performance Shares of NASDAQ:HRTX opened at $3.20 on Monday. The stock has a market cap of $482.08 million, a price-to-earnings ratio of -5.25 and a beta of 1.73. The company has a 50 day moving average of $2.78 and a 200-day moving average of $2.21. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.29. Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.08. The firm had revenue of $34.23 million for the quarter, compared to analyst estimates of $30.98 million. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. SG Americas Securities LLC acquired a new position in shares of Heron Therapeutics in the 3rd quarter valued at $31,000. Commonwealth Equity Services LLC increased its holdings in shares of Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Heron Therapeutics by 5.8% during the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 19,345 shares during the period. Richmond Brothers Inc. lifted its holdings in shares of Heron Therapeutics by 142.9% during the 3rd quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 60,604 shares in the last quarter. Finally, Monaco Asset Management SAM grew its position in shares of Heron Therapeutics by 72.1% in the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 291,908 shares during the period. Institutional investors own 80.01% of the company’s stock. About Heron Therapeutics (Get Free Report) Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. See Also Five stocks we like better than Heron Therapeutics Stock Dividend Cuts Happen Are You Ready? MarketBeat Week in Review – 5/13 – 5/17 What is the Dow Jones Industrial Average (DJIA)? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Warren Buffett Stocks to Buy Now Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
